The COVID-19 pandemic thrust messenger RNA (mRNA) vaccines into the global spotlight, revolutionizing vaccine development with unprecedented speed and efficacy. Following swift clinical trials, the first COVID-19 mRNA vaccine was administered on December 8, 2020, marking a pivotal moment in public health history. Researchers subsequently estimated through sophisticated modeling, published in studies such as one in The Lancet Infectious Diseases, that these groundbreaking vaccines prevented at least 14.4 million deaths worldwide during their inaugural year of deployment. This remarkable achievement, which also saw the pioneering scientists behind mRNA technology, Katalin Karikó and Drew Weissman, awarded the Nobel Prize in Physiology or Medicine in 2023, underscored the profound potential of genetic vaccines. The mRNA Revolution and Its Unforeseen Limitations The profound impact of mRNA vaccines on the global health crisis spurred scientists to rapidly develop similar platforms for a spectrum of other infectious diseases. Ongoing clinical trials are now targeting a diverse array of pathogens, including influenza virus, Respiratory Syncytial Virus (RSV), human immunodeficiency virus (HIV), Zika virus, Epstein-Barr virus, and even tuberculosis bacteria, reflecting a broad optimism for this innovative technology. However, extensive real-world application and continued study of COVID-19 mRNA vaccines have simultaneously unveiled important limitations, highlighting an urgent need for new and complementary vaccine strategies to overcome persistent hurdles in global health preparedness and response. Navigating the Challenges of mRNA Vaccine Performance and Production Despite their initial triumph, mRNA vaccines present several critical challenges that warrant innovative solutions. Immunological protection generated by COVID-19 mRNA vaccines can vary widely among individuals, influenced by factors such as age, underlying health conditions, and genetic predispositions. Furthermore, this protection is not indefinite, necessitating booster shots and updated formulations as immunity wanes over time. This issue is compounded by the relentless evolution of SARS-CoV-2, the virus responsible for COVID-19. New variants, such as Omicron sublineages like BA.2.86 (Pirola) and JN.1, continuously emerge with mutations that allow them to partially evade existing immune defenses, including those induced by prior vaccination or infection. This evolutionary arms race means that vaccine formulations often require frequent updates, posing a significant logistical and manufacturing burden. Beyond the immunological aspects, practical challenges associated with mRNA vaccine technology are substantial. Manufacturing mRNA vaccines is a complex and expensive process, requiring specialized facilities and stringent quality control. A particular difficulty lies in precisely controlling the number of mRNA molecules packaged into lipid nanoparticles (LNPs), which are essential for delivering the genetic material into cells. These LNPs also contribute to the vaccines’ notorious requirement for ultra-cold storage, typically at temperatures ranging from -80°C to -60°C. This "cold chain" requirement poses immense logistical hurdles, particularly for distribution in remote areas or low-income countries where access to specialized refrigeration infrastructure is limited or non-existent. Additionally, while generally safe, mRNA vaccines may cause unintended off-target effects or reactogenicity, prompting continuous monitoring and research into their long-term profiles. Overcoming these multifaceted limitations is crucial for enhancing global preparedness and ensuring equitable and effective responses to future infectious disease threats. Introducing DoriVac: A DNA Origami Vaccine Platform Offering a Novel Alternative To directly address these emerging challenges, a multidisciplinary team comprising researchers from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and their partner institutions has pioneered a fundamentally different approach. They have developed a groundbreaking DNA origami nanotechnology platform known as DoriVac, which functions innovatively as both a vaccine and an intrinsic adjuvant. This dual functionality represents a significant leap forward in vaccine design, promising enhanced immune responses and improved practical characteristics. The researchers strategically designed initial DoriVac vaccines to target a specific peptide region called HR2, a highly conserved sequence found within the spike proteins of several formidable viruses, including SARS-CoV-2, HIV, and Ebola. This focus on conserved regions is critical for developing broadly protective vaccines that are less susceptible to viral mutations. Preclinical studies conducted in mice demonstrated that the SARS-CoV-2 HR2 DoriVac vaccine triggered exceptionally strong and broad immune responses, encompassing both antibody-driven (humoral) and T cell-driven (cellular) activity. Humoral immunity, mediated by antibodies, is crucial for neutralizing viruses circulating in the bloodstream, while cellular immunity, involving T cells, is vital for clearing infected cells and providing long-term protection. To further validate its potential in a more human-relevant context, the team rigorously tested the DoriVac vaccine in a preclinical human model utilizing the Wyss Institute’s advanced microfluidic human Organ Chip technology. This innovative system, specifically a human lymph node-on-a-chip, precisely simulates aspects of the human immune system in an in vitro environment. In this sophisticated system, the SARS-CoV-2 HR2 DoriVac vaccine also consistently generated robust antigen-specific immune responses in human cells, providing compelling evidence of its potential human efficacy. A critical phase of the research involved a direct comparison between a DoriVac vaccine carrying the same SARS-CoV-2 spike protein variant and established SARS-CoV-2 mRNA vaccines delivered through lipid nanoparticles. While both platforms produced similarly strong immune activation in the human models, the DNA origami vaccine showcased distinct advantages in terms of stability, ease of storage, and manufacturing simplicity. These significant findings, which hold profound implications for the future of vaccine technology and global health equity, were meticulously reported in the prestigious journal Nature Biomedical Engineering. The Genesis of DoriVac: Precision Engineering at the Nanoscale "With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages, including an unprecedented control over vaccine composition, and the ability to program immune recognition in targeted immune cells on a molecular level to achieve better responses," stated co-corresponding author and Wyss Institute Core Faculty member William Shih, Ph.D., whose pioneering group conceptualized the new vaccine. "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses." Dr. Shih also holds a professorship at Harvard Medical School and DFCI, underscoring the collaborative nature of this breakthrough. The journey of DoriVac began in 2024 when Shih’s team at the Wyss Institute and Dana-Farber first introduced it as a DNA nanotechnology-based vaccine platform with broad potential applications. Yang (Claire) Zeng, M.D., Ph.D., who spearheaded this monumental effort alongside collaborators, demonstrated DoriVac’s unique capability to precisely present immune-stimulating adjuvant molecules to cells at the nanoscale. This exquisite control over molecular presentation is a hallmark of DNA origami technology, allowing for the precise arrangement of biological components with unparalleled accuracy. Earlier foundational studies, primarily focused on cancer applications in tumor-bearing mice, had already revealed that these DNA origami-based vaccines produced significantly stronger immune responses than conventional vaccine versions lacking the intricate DNA origami structure. DoriVac vaccines are ingeniously constructed from tiny, self-assembling square DNA nanostructures. One side of these nanostructures is meticulously designed to display adjuvant molecules, arranged at carefully controlled nanometer distances—a critical feature for optimal immune cell activation. The opposite side of the nanostructure is then engineered to present selected antigens, such as peptides or proteins derived from tumors or pathogens, thereby guiding the immune system’s response. "While we were developing the platform for cancer applications, the COVID-19 pandemic was still moving with full force. So, the question quickly arose whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings," explained Dr. Zeng, who served as a first and co-corresponding author on the new study. Dr. Zeng is now the cofounder and CEO/CTO of DoriNano, a spin-off company dedicated to translating this cutting-edge technology into clinical applications, signaling a clear path towards real-world impact. To explore this compelling idea, Dr. Zeng and co-first author Olivia Young, Ph.D., a former graduate student in Shih’s group, initiated a collaborative effort with Donald Ingber’s team at the Wyss Institute. Dr. Ingber’s group is renowned for its innovative work in antiviral research, employing sophisticated AI-driven and multiomics approaches in conjunction with their pioneering microfluidic human Organ Chip systems. Working together with co-first author Longlong Si, Ph.D., a former postdoctoral researcher in Ingber’s lab, the researchers developed DoriVac vaccines specifically targeting SARS-CoV-2, HIV, and Ebola. These vaccine candidates were engineered to present the HR2 peptides, which act as highly conserved antigens within the respective viral spike proteins, offering a strategy for broad and durable protection. "Our analysis of the immune responses provoked by these first DoriVac vaccines in mice led to several encouraging observations, including significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce," Dr. Zeng elaborated. "We found that the numbers of antibody-producing B cells, activated antigen-presenting dendritic cells (DCs), and antigen-specific memory and cytotoxic T cell types that are vital for long-term protection were all increased, especially in the case of the SARS-CoV-2 HR2," she further explained, emphasizing the comprehensive nature of the immune activation. From Mouse Models to Human Relevance: The Power of Organ Chips A persistent and formidable challenge in vaccine development has historically been the translational gap between animal models and human physiology. Immune responses observed in mice, while informative, often do not fully reflect the complexities of the human immune system, leading to numerous promising treatments failing during subsequent clinical trials. To bridge this critical gap and improve the predictability of human outcomes, the DoriVac team ingeniously tested their vaccines using a sophisticated human lymph node-on-a-chip (human LN Chip), a hallmark technology developed at the Wyss Institute that meticulously mimics key aspects of the human immune system in a controlled, in vitro environment. This advanced system, further refined by co-first author Min Wen Ku and co-corresponding author Girija Goyal, Ph.D., Director of Bioinspired Therapeutics at the Wyss Institute, provided invaluable insights. The human LN Chip demonstrated that the SARS-CoV-2-HR2 DoriVac vaccine effectively activated human dendritic cells (DCs) and significantly boosted their production of inflammatory cytokines—signaling molecules crucial for initiating and orchestrating immune responses—when compared with control groups receiving origami-free components. Moreover, the DoriVac vaccine led to an increased proliferation of CD4+ and CD8+ T cells, both of which possess multiple protective functions vital for adaptive immunity, further strengthening the platform’s potential for successful human application. "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines, and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines. This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments," affirmed co-corresponding author Donald Ingber, M.D., Ph.D. Dr. Ingber, a distinguished figure in bioengineering, holds the Judah Folkman Professorship of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and is also the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, highlighting the interdisciplinary excellence driving this research. DoriVac vs. mRNA: A Head-to-Head Comparison with Promising Results In a crucial phase of their investigation, the researchers also evaluated a DoriVac vaccine designed to present the full SARS-CoV-2 spike protein, directly pitting it against the widely adopted Moderna and Pfizer/BioNTech mRNA lipid nanoparticle (LNP) vaccines that encode the identical spike protein. This head-to-head comparison was vital for understanding DoriVac’s competitive standing against the current gold standard of genetic vaccines. Utilizing a standard booster immunization approach in mice, both vaccine types demonstrated remarkably similar antiviral T cell and antibody-producing B cell responses. This parity in immune efficacy is a powerful testament to DoriVac’s ability to generate robust protective immunity comparable to that of established mRNA vaccines. "This underscored DoriVac’s potential as a DNA nanotechnology-enabled, self-adjuvanted vaccine platform. But DoriVac vaccines have a number of other advantages: they don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones," emphasized Dr. Shih. The absence of cold-chain requirements is a monumental advantage, potentially democratizing vaccine access globally by eliminating the need for expensive ultra-cold freezers and specialized logistics, which have been significant barriers during past pandemics. Furthermore, the simpler manufacturing process for DoriVac, based on DNA synthesis rather than complex LNP encapsulation, promises reduced costs and increased scalability. Recent studies conducted at DoriNano have also provided encouraging data, demonstrating that DoriVac exhibits a promising safety profile, a critical factor for any new vaccine technology. Broader Implications and the Future Landscape of Vaccinology The emergence of the DoriVac platform carries profound implications for global health equity and pandemic preparedness. The ability to store and transport vaccines at ambient temperatures would drastically simplify distribution, particularly in low-income countries where cold-chain infrastructure is often inadequate. This could lead to a significant reduction in vaccine waste and a dramatic increase in access, addressing a critical lesson learned from the COVID-19 pandemic where vaccine equity remained a major challenge. Beyond logistics, DoriVac’s "flexible chassis" design, allowing for precise control over vaccine composition and rapid antigen switching, could significantly accelerate responses to future outbreaks. In the face of rapidly evolving pathogens, a platform that can be quickly adapted and manufactured efficiently at scale would be invaluable for containing emerging threats before they escalate into global crises. The DoriVac technology, originating from cancer research, also hints at broader applications beyond infectious diseases, potentially extending to therapies for autoimmune disorders or other complex conditions where precise immune modulation is required. While the preclinical results are exceptionally promising, the DoriVac platform still faces the rigorous journey of clinical trials to confirm its safety and efficacy in humans. Navigating regulatory hurdles, scaling up manufacturing for global demand, and conducting large-scale real-world effectiveness studies will be the next critical steps. However, the collaborative, multidisciplinary approach adopted by the Wyss Institute, Dana-Farber Cancer Institute, and their partners, coupled with the establishment of DoriNano, positions this technology strongly for future translation. DoriVac represents a significant stride towards a new generation of vaccines that are not only highly effective but also universally accessible, ushering in an era of enhanced global health resilience. Other contributing authors to this pivotal study include Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon. The research was made possible through generous funding from the Director’s Fund and Validation Project program of the Wyss Institute; the Claudia Adams Barr Program at DFCI; the National Institutes of Health (U54 grant CA244726-01); the US-Japan CRDF global fund (grant R-202105-67765); the National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); the Intramural Research Program of the Korea Institute of Science and Technology (KIST); and the Bill and Melinda Gates Foundation (INV-002274). Post navigation Sertraline Shows Early Modest Improvement in Key Depression and Anxiety Symptoms Within Two Weeks, UCL-Led Analysis Reveals.
